Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

被引：7

作者：

Arbour, Kathryn Cecilia

Ricciuti, Biagio

Rizvi, Hira

Hellmann, Matthew D.

Yu, Helena Alexandra

Ladanyi, Marc

Kris, Mark G.

Arcila, Maria E.

Rudin, Charles M.

Lito, Piro

Awad, Mark M.

Riely, Gregory J.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

[3] Massachusetts Gen Hosp, Cambridge, MA USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9088

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9088

引用

页数：2